HomeCONGRESS

CONGRESS

View Category
Coronary disease

ACC 2021 | RAPID-TnT: Usefulness of High-Sensitivity Ultra-Fast Troponin T

Patients under evaluation for acute coronary syndrome (ACS) without clear ischemia signs in an electrocardiogram find no...
solaci -
Learn More
Femoropopliteal

ACC 2021 | SAFE-PAD: Paclitaxel-Eluting Devices in Peripheral Disease

This work was conducted alongside the US Food and Drug Administration (FDA) to investigate the association between...
solaci -
Learn More
Antithrombotic Anticoagulants

ACC 2021 | ATLANTIS: Apixaban After TAVR vs. Standard of Care

Adding apixaban to the treatment of patients undergoing transcatheter aortic valve replacement (TAVR) was non-superior to standard...
solaci -
Learn More
Antiplatelet

ACC 2021 | ADAPTABLE: Low Doses of Aspirin Are Equally Effective and Present Lower Bleeding Risk

Patients diagnosed with cardiovascular disease taking aspirin as secondary prevention can take lower doses and achieve the...
solaci -
Learn More
Acute coronary syndromes

ACC 2021 | TALOS-AMI: De-escalating from Ticagrelor to Clopidogrel after One Month

After one-month dual antiplatelet therapy (DAPT) with aspirin and ticagrelor, a net clinical benefit was observed when...
solaci -
Learn More
Other

ACC 2021 | Relive Renal Denervation with RADIANCE-HTN TRIO

Endovascular ultrasound renal denervation significantly reduces systolic blood pressure when compared against a sham procedure according to...
solaci -
Learn More
Acute coronary syndromes

ACC 2021 | Sacubitril/Valsartan not Superior to Ramipril after AMI

The combination sacubitril/valsartan following high-risk AMI did not reduce the risk of cardiac failure or cardiovascular risk in...
solaci -
Learn More
Acute coronary syndromes

ACC 2021 | Emergent CABG for acute MI: Benefits Despite Risk

The latest figures show a lower number of emergency CABG for acute MI, and in turn increased...
solaci -
Learn More